Oriola Oyj Past Earnings Performance
Past criteria checks 0/6
Oriola Oyj's earnings have been declining at an average annual rate of -48.6%, while the Healthcare industry saw earnings growing at 8.4% annually. Revenues have been declining at an average rate of 3.3% per year.
Key information
-48.6%
Earnings growth rate
-48.6%
EPS growth rate
Healthcare Industry Growth | 13.4% |
Revenue growth rate | -3.3% |
Return on equity | -15.1% |
Net Margin | -1.5% |
Next Earnings Update | 30 Oct 2024 |
Recent past performance updates
Recent updates
Oriola Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jul 21Oriola Oyj (HEL:OKDBV) Is Paying Out A Larger Dividend Than Last Year
Feb 19Oriola Oyj (HEL:OKDBV) Is Increasing Its Dividend To €0.06
Feb 19Oriola Oyj (HEL:OKDBV) Has Announced That It Will Be Increasing Its Dividend To €0.04
Feb 20Oriola Oyj (HEL:OKDBV) Is Finding It Tricky To Allocate Its Capital
Jun 07Oriola Oyj (HEL:OKDBV) Shares Could Be 25% Below Their Intrinsic Value Estimate
Mar 26Oriola Oyj (HEL:OKDBV) Is About To Go Ex-Dividend, And It Pays A 1.4% Yield
Mar 12Are Investors Concerned With What's Going On At Oriola Oyj (HEL:OKDBV)?
Mar 06Oriola Oyj Just Missed Earnings - But Analysts Have Updated Their Models
Feb 20Should You Be Worried About Oriola Oyj's (HEL:OKDBV) 4.6% Return On Equity?
Feb 17What Type Of Shareholders Own The Most Number of Oriola Oyj (HEL:OKDBV) Shares?
Feb 01Does Oriola Oyj's (HEL:OKDBV) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 19Are Dividend Investors Getting More Than They Bargained For With Oriola Oyj's (HEL:OKDBV) Dividend?
Jan 06Is Oriola Oyj (HEL:OKDBV) A Risky Investment?
Dec 24An Intrinsic Calculation For Oriola Oyj (HEL:OKDBV) Suggests It's 37% Undervalued
Dec 12How Much Did Oriola Oyj's(HEL:OKDBV) Shareholders Earn From Share Price Movements Over The Last Five Years?
Nov 29Revenue & Expenses Breakdown
How Oriola Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 1,560 | -23 | 59 | 0 |
31 Mar 24 | 1,510 | -24 | 60 | 0 |
31 Dec 23 | 1,495 | -21 | 59 | 0 |
30 Sep 23 | 1,500 | -26 | 60 | 0 |
30 Jun 23 | 1,522 | 0 | 61 | 0 |
31 Mar 23 | 1,527 | 4 | 63 | 0 |
31 Dec 22 | 1,540 | 5 | 67 | 0 |
30 Sep 22 | 1,528 | 17 | 71 | 0 |
30 Jun 22 | 1,513 | 16 | 73 | 0 |
31 Mar 22 | 1,479 | 11 | 76 | 0 |
31 Dec 21 | 1,452 | 9 | 78 | 0 |
30 Sep 21 | 1,532 | 9 | 119 | 0 |
30 Jun 21 | 1,612 | 8 | 145 | 0 |
31 Mar 21 | 1,688 | 6 | 170 | 0 |
31 Dec 20 | 1,801 | 11 | 195 | 0 |
30 Sep 20 | 1,782 | 7 | 199 | 0 |
30 Jun 20 | 1,772 | 5 | 200 | 0 |
31 Mar 20 | 1,784 | 11 | 200 | 0 |
31 Dec 19 | 1,722 | 8 | 199 | 0 |
30 Sep 19 | 1,669 | -2 | 200 | 0 |
30 Jun 19 | 1,610 | 8 | 197 | 0 |
31 Mar 19 | 1,561 | 9 | 196 | 0 |
31 Dec 18 | 1,552 | 11 | 195 | 0 |
30 Sep 18 | 1,553 | 23 | 196 | 0 |
30 Jun 18 | 1,560 | 19 | 197 | 0 |
31 Mar 18 | 1,549 | 22 | 196 | 0 |
31 Dec 17 | 1,528 | 26 | 196 | 0 |
30 Sep 17 | 1,544 | 35 | 192 | 0 |
30 Jun 17 | 1,549 | 38 | 187 | 0 |
31 Mar 17 | 1,569 | 40 | 183 | 0 |
31 Dec 16 | 1,589 | 42 | 178 | 0 |
30 Sep 16 | 1,598 | 43 | 172 | 0 |
30 Jun 16 | 1,593 | 46 | 170 | 0 |
31 Mar 16 | 1,603 | 47 | 169 | 0 |
31 Dec 15 | 1,627 | 45 | 170 | 0 |
30 Sep 15 | 1,624 | 50 | 144 | 0 |
30 Jun 15 | 1,636 | 47 | 144 | 0 |
31 Mar 15 | 1,625 | 45 | 144 | 0 |
31 Dec 14 | 1,613 | 45 | 144 | 0 |
30 Sep 14 | 896 | 44 | 106 | 0 |
30 Jun 14 | 1,160 | 35 | 119 | 0 |
31 Mar 14 | 1,407 | 24 | 87 | 0 |
31 Dec 13 | 1,620 | 17 | 137 | 0 |
30 Sep 13 | 2,627 | 12 | 242 | 0 |
Quality Earnings: OKDBV is currently unprofitable.
Growing Profit Margin: OKDBV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OKDBV is unprofitable, and losses have increased over the past 5 years at a rate of 48.6% per year.
Accelerating Growth: Unable to compare OKDBV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OKDBV is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-0.8%).
Return on Equity
High ROE: OKDBV has a negative Return on Equity (-15.12%), as it is currently unprofitable.